VMD Sciences announced expanded efforts to support large animal veterinarians facing ongoing pharmaceutical shortages and emerging infectious disease challenges, including limited availability of equine colic therapies and the spread of Theileriosis linked to the Asian longhorned tick.
Summary
- VMD Sciences is expanding support for veterinarians managing drug shortages and emerging disease threats.
- The company cited an ongoing reported U.S. shortage of Buscopan® used in equine colic management.
- VMDS said it is helping veterinarians access EU-approved Buscopan® Compositum Solution for Injection through compliant importation pathways.
- The company is also addressing growing concerns surrounding Theileriosis associated with the spread of the Asian longhorned tick.
- VMDS stated that all sourcing and distribution efforts are conducted in accordance with applicable importation regulations and compliance standards.
VMD Sciences (VMDS) announced expanded initiatives aimed at helping large animal veterinarians maintain access to critical therapeutics as supply chain disruptions and emerging infectious diseases continue to impact veterinary medicine in the United States.
The company said one of its immediate priorities is helping equine practitioners address the reported domestic shortage of Buscopan®, a therapy commonly used in equine colic management. To support continuity of care, VMDS is facilitating access to Buscopan® Compositum Solution for Injection, an EU-approved alternative available through compliant importation pathways.
According to VMDS, the effort is intended to help veterinarians avoid treatment disruptions caused by domestic supply limitations while maintaining regulatory compliance.
Focus on Emerging Infectious Disease Threats
In addition to pharmaceutical shortages, VMDS said it is increasing its focus on emerging vector-borne diseases affecting herd health, particularly Theileriosis associated with the spread of the Asian longhorned tick across multiple U.S. regions.
The company stated that expanding access to internationally licensed antiparasitic and related therapies may help veterinarians respond to disease threats for which limited domestic treatment options currently exist.
VMDS said it works with veterinarians to navigate regulatory and logistical requirements tied to international medication importation, helping facilitate access to global manufacturers and licensed distributors when clinically appropriate.
“Our goal is to ensure veterinarians are never placed in a position where patient care is delayed or compromised due to supply shortages or emerging disease pressures,” said Ricky Falcha, president of VMD Sciences. “Large animal practice depends on consistent access to proven, effective therapies, and we are committed to responsibly expanding those options while helping maintain the highest standards of regulatory compliance.”
The company emphasized that all sourcing and distribution activities are conducted in accordance with importation regulations, with focus on safety, compliance, and product traceability.
VMD Sciences said it will continue expanding efforts to support veterinarians facing evolving supply chain challenges and infectious disease risks affecting large animal medicine.
Information sourced from the company’s press release.
